Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1321-1340 of 1,743 trials

Soft Tissue Sarcoma: Doxorubicin Chemotherapy Study

We are investigating whether adding doxorubicin-based chemotherapy helps patients with high-risk localized soft tissue sarcoma live longer without metastasis. This study compares it to standard treatment to assess safety and effectiveness.

Soft Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOncology

Chronic Myeloid Leukemia: Second Stop of TKI Treatment

We are studying whether patients with CML can maintain remission after stopping their medication for a second time. This trial aims to identify factors that may help in achieving better treatment outcomes.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Heart Failure: Hyperpolarized MRI Study

We are investigating how the heart uses a substance called pyruvate in patients with heart failure. This study aims to see if a new imaging method can improve our understanding of heart metabolism.

Heart Failure>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Obesity: BI 456906 vs. Semaglutide

We are testing a new medication, BI 456906, in people with obesity to see how it affects liver function compared to semaglutide. This study aims to understand the potential benefits of different doses for managing obesity.

Obesity>2 yearsSafety phase (I)EndocrinologyInternal Medicine

HIV-1 Control: Genetic and Immune Response Study

We are studying early-treated HIV-1 patients who stopped their antiretroviral therapy to find out if specific genetic and immune markers can predict their ability to control the virus. This research may help improve future treatment strategies.

HIV Positive During Acute Phase>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious Diseases

Erectile Rehabilitation with Sildenafil After Rectal Cancer Surgery

We are studying whether Sildenafil can help men maintain erectile function after proctectomy for rectal cancer. This trial will evaluate its effects on sexual health and quality of life over the year following surgery.

Men Treated with Proctectomy for Rectal Cancer>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementOncologyUrology

Gastrointestinal Stromal Tumor: Adjuvant Imatinib Study

We are studying whether adjuvant Imatinib can help prevent cancer recurrence in patients with intermediate-risk gastrointestinal stromal tumors. This trial compares its effects on survival and quality of life against standard treatments.

Gastrointestinal Stromal Tumor>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Gestational Trophoblastic Neoplasias: Avelumab and Methotrexate Study

We are investigating a new treatment combining Avelumab and Methotrexate for individuals with low-risk gestational trophoblastic neoplasias. This study aims to see if this combination is a safe and effective first-line option.

Gestational Trophoblastic Tumor>2 yearsSafety phase (I)Efficacy phase (II)Gynecology and Obstetrics

Primary Immune Thrombocytopenia: Efgartigimod IV Study

We are testing the safety and effectiveness of efgartigimod IV in adults with primary immune thrombocytopenia. This study will help us understand if it can improve platelet counts and reduce bleeding risks.

Idiopathic Thrombocytopenic Purpura (ITP)>2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementHematologyInternal Medicine

Ongoing Safety Study for Patients in Previous Trials

We are monitoring the safety of a treatment for patients who have participated in earlier studies. This study aims to ensure continued support and care for their health.

Chronic Lymphocytic Leukemia (CLL)B-cell Non-Hodgkin's Lymphoma (NHL)>2 yearsSafety phase (I)Post-Trial Drug AccessHematologyOncology

Glioblastoma: 131I-TLX101 Treatment Study

We are testing a new treatment combined with standard care for patients newly diagnosed with glioblastoma. The goal is to find a safe dose and understand how well it works.

Glioblastoma Multiforme>2 yearsSafety phase (I)Oncology

Aggressive Multiple Sclerosis: Stem Cell Transplant Study

We are investigating whether stem cell transplantation can prevent disease activity in people with aggressive multiple sclerosis. The study will also monitor safety and other health changes over time.

Relapsing-Remitting Multiple Sclerosis>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyNeurology

Artificial Cornea for Severe Corneal Ulcers

We are studying a new human-made cornea for patients with advanced corneal ulcers that don't improve with standard treatments. The trial aims to assess its safety and effectiveness in these challenging cases.

Corneal Ulcer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Advanced Neuroendocrine Carcinomas: Enfortumab-Vedotin Study

We are studying a new treatment for patients with advanced Neuroendocrine Carcinomas who cannot use standard chemotherapy. The goal is to see if this treatment can help shrink tumors and improve survival.

Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesEndocrinologyOncology

Diffuse Large B-Cell Lymphoma: Zilovertamab Vedotin with R-CHP

We are studying a new treatment combining zilovertamab vedotin with standard therapy for people with diffuse large B-cell lymphoma. The goal is to see if this combination works better than another treatment option.

Diffuse Large B-Cell Lymphoma>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

HPV 16: FluBHPVE6E7 Vaccine Study

We are testing different doses of a new vaccine for women infected with HPV 16. The goal is to see if it helps improve their condition compared to a placebo.

Human Papilloma Virus Infection>2 yearsSafety phase (I)Gynecology and ObstetricsInfectious Diseases

Epiflux: Investigating a New Treatment

We are exploring a new treatment called Epiflux for patients with a specific health condition. Our goal is to understand its effects and potential benefits compared to existing options.

Focal Epilepsy>2 yearsEfficacy phase (II)Neurology

Gout Treatment: Immediate vs. Delayed Febuxostat

We are studying whether starting febuxostat right after a gout attack helps reduce the number of gout days compared to starting it six weeks later. This trial is for individuals experiencing acute gout attacks.

Gout>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOrthopedics and TraumatologyRheumatology

Juvenile Idiopathic Arthritis: Biosimilar vs. Original Medications

We are studying whether switching between biosimilar and original anti-TNF medications helps children with Juvenile Idiopathic Arthritis maintain disease control. The trial will evaluate safety, effectiveness, and the occurrence of side effects.

Juvenile Idiopathic Arthritis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesRheumatology

Ischemic Stroke: DOAC Intravenous Thrombolysis Trial

We are studying whether intravenous thrombolysis is more effective than standard care for patients with ischemic stroke who have recently taken direct oral anticoagulants. This research aims to improve recovery outcomes for these patients.

Acute Ischemic Stroke>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNeurology